NTRB Logo.png
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
February 11, 2025 09:00 ET | Nutriband Inc.
ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European...
Evolveimmune.png
EvolveImmune Appoints Kristen M. Hege, M.D. to Its Board of Directors
February 11, 2025 08:00 ET | EvolveImmune Therapeutics
BRANFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immunotherapy company developing first-in-category, multifunctional T Cell engager biotherapeutics to address unmet...
Logo.png
Bind Research launched to transform disordered proteins into effective drug targets
February 11, 2025 04:00 ET | Bind Research
Bind Research launched to transform disordered proteins into effective drug targets UK’s first not-for-profit Focused Research Organisation supported by Department for Science, Research and...
Alumis.png
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025 16:45 ET | Alumis Inc.
Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
NTRB Logo.png
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
February 07, 2025 08:45 ET | Nutriband Inc.
U.S. Patent Office issues Notice of Allowance for new patent covering Nutriband's AVERSA™ technology
Alumis.png
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025 16:15 ET | Alumis Inc.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
PharmAla Biotech Logo 800 x 422.png
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025 16:06 ET | PharmAla Biotech
PharmAla adds Matthew Azrieli to Advisory Team
BioNTX StandardMed_Res.jpg
North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences
February 06, 2025 10:00 ET | BioNTX
DALLAS, Feb. 06, 2025 (GLOBE NEWSWIRE) -- From January 20-23, 2025, North Texas took center stage as a global hub for innovation during Advanced Therapies Week (ATW) 2025. This signature event...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
February 06, 2025 08:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
February 06, 2025 06:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus